Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HEC585 dose A · 1 trial · 1 indication
change in FVC (mL), measured using Spirometer, from baseline to week 24
| Arm | Type | Description |
|---|---|---|
| HEC585 tables does A | EXPERIMENTAL | - |
| HEC585 tables does B | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | Placebo once daily up to 24 weeks in main stage; HEC585 dose A once daily up to 96 weeks in extended stage |
| Name | Type | Description |
|---|---|---|
| HEC585 dose A | DRUG | taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage |
| HEC585 dose B | DRUG | taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage |
| Placebo | DRUG | taking Placebo orally once daily, up to 24 weeks in main stage |
Inclusion Criteria: 1. Volunteer to participate and sign the ICF. 2. Male or female patients' age ≥ 18 years when signing the ICF. 3. Patients with known or unknown etiology (except IPF) and clear pulmonary fibrosis on chest CT have undergone conventional clinical treatment (assessed by the investi...
HEC585 dose A is an investigational small molecule being studied for the treatment of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) and Progressive Pulmonary Fibrosis (PPF). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
HEC585 dose A is being developed by Sunshine Biopharma Inc., a company listed on the stock exchange under the ticker symbol SBFM. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with PF-ILD and PPF.
HEC585 dose A is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being evaluated in clinical trials for the treatment of Progressive Fibrosing Interstitial Lung Disease and Progressive Pulmonary Fibrosis.
HEC585 dose A is being studied in a Phase 2 clinical trial registered as NCT05139719. This randomized, double-blind, placebo-controlled trial is recruiting approximately 110 participants in China to evaluate the drug's effect on delaying forced vital capacity decline in patients with PF-ILD and PPF.
HEC585 dose A is a specific dose of the drug HEC585. The clinical trial NCT05139719 is designed to explore the therapeutic effect of HEC585 on delaying forced vital capacity decline in patients with Progressive Fibrosing Interstitial Lung Disease, and HEC585 dose A refers to one of the doses being tested in this study.